Participated · Series B · Mar 2023

Sirius Medical develops the Sirius Pintuition surgical navigation platform and GPSDetect software to enable wire‑free localization for breast‑conserving surgery. The Pintuition system is CE marked and FDA cleared and has been praised by breast cancer surgeons. The company traces its roots to the Netherlands Cancer Institute and reports adoption in over 250 centers and 35,000 procedures globally. Sirius Medical is focused on improving usability and extending applications of its platform. The company announced it secured €10M in additional scale‑up funding to support product development and global expansion. The investment will also be used to bolster sales infrastructure and enter new markets. Sirius Medical develops Pintuition, a surgical marker navigation system that gives surgeons real-time distance and directional guidance to locate tumors. The company is led by CEO Bram Schermers and is focused on improving care for cancer patients by enabling precise and efficient tumor removal. Pintuition is active in over 100 centers with more than 5,000 procedures across Western Europe and the US. Sirius experienced revenue growth in 2022 and has built an international sales network in Europe and the USA. The company plans to use new funding to accelerate worldwide growth of Pintuition, support further product development, and expand commercial roll-out. Sirius Medical has commercially launched the Sirius Pintuition System, a localisation platform designed to help surgeons pinpoint breast tumours during surgery. The system is CE marked and Sirius is pursuing FDA clearance. The Pintuition seed can be placed up to 180 days before surgery and the intraoperative probe gives real-time feedback and directional guidance to marked tissue. Sirius positions Pintuition as an easy-to-use, affordable alternative to metal anchor wires and radioactive seeds, aiming to improve hospital workflow and surgical accuracy. The company is developing a pipeline of complementary products and indications alongside the commercial rollout. Management says recent funding will be used to execute growth plans and advance the product pipeline.

Participated · Debt Financing · Mar 2023

Lunaphore, led by CEO Ata Tuna Ciftlik, develops chip-based solutions that extract spatial proteomic and transcriptomic data from tumors and other tissues. Its platform transforms standard assays into multiplex spatial biology to support research in immunology, immuno-oncology, and neuroscience. The technology enables identification of biomarker signatures with clinical relevance to aid diagnostic development and streamline clinical trials. Lunaphore intends to use the new funding to strengthen its spatial biology portfolio and to support commercial execution to meet customer demand. The company recently completed a CHF40M first close of a Series D that includes a EUR10M venture debt facility. Lunaphore Technologies develops next-generation tissue autostainers using a microfluidics-based technology called FFeX (Fast Fluidic Exchange). The FFeX platform is designed to perform assays much faster than standard techniques and has shown promising results in tests with cancer patient samples. The company focuses on equipment for cancer research and tissue diagnostics and is working on next-generation instruments. Founded in 2014 and based in Lausanne, Switzerland, Lunaphore plans to use recent funds for market and product expansion, including a US market entry and a ramp-up of activities in Europe. Financially, the company completed a Series C2 closing that added CHF2M and contributed to a CHF25M total Series C round. The Swiss Entrepreneurs Fund invested in the Series C2 and has committed a total of CHF5M to Lunaphore. Lunaphore Technologies develops next‑generation tissue autostainers based on its FFeX (Fast Fluidic Exchange) microfluidics technology to perform assays faster than standard techniques and has demonstrated promising results with cancer patient samples. The company is based in Lausanne, Switzerland and was founded in 2014. It focuses on products for tissue analytics, pathology workflows and immuno‑oncology research. Lunaphore plans to use the Series C proceeds for market and product expansion, including a US market entry, ramping up activities in Europe and developing next‑generation instruments. The company completed a first closing of a CHF 23M Series C financing on January 15, 2020 (the round was oversubscribed). Lunaphore designs next-generation devices for cancer tissue diagnostics, including a precision medicine solution that performs ultra-rapid immunostainings. The company intends to use the new funding to obtain CE marking and support a product launch. Management says the financing validates partnerships announced in recent months and will help drive market adoption of its first products. The round was oversubscribed and finalized in August 2018. Lunaphore’s CEO, Ata Tuna Ciftlik, and board members highlighted progress toward commercialisation and market launch in the coming months. Lunaphore develops devices based on microfluidic tissue processor technology aimed at shortening the time required for cancer diagnostics assays while maintaining high precision. The company has tested its technology in collaboration with key opinion leaders and across laboratories and hospitals internationally. Lunaphore intends to use the recently raised funds for the development and market introduction of its devices. The company was founded in 2014 by Dr. Ata Tuna Ciftlik, who serves as CEO. Lunaphore is headquartered in Lausanne, Switzerland and focuses on translating its microfluidic platform into clinical diagnostic workflows. No operating metrics were disclosed in the article.

Led · Debt Financing · Jun 2018

Caresyntax offers a vendor-neutral precision surgery platform led by CEO Dennis Kogan. Its proprietary software and AI captures and analyzes large volumes of video, audio, images, device, clinical and operational data in and around the operating room to deliver actionable insights, meta-data and real-world evidence. The software and automation platform can be used live during procedures and accessed by users outside the OR via secured dedicated cloud and telehealth links. The platform aims to help surgeons and care teams improve patient outcomes, enable hospital administrators to use resources more efficiently, assist medical device companies to advance products, and support insurers in understanding and controlling risks and enabling value-based contracts. Caresyntax serves over 30,000 surgical professionals across more than 3,000 operating rooms worldwide. The company raised $180M in Series C financing and intends to use the funds to expand operations and its development efforts. Caresyntax provides a digital surgery platform that uses proprietary software and artificial intelligence to analyze large volumes of video, audio, images, device, clinical, and operational data in and around the operating room. The platform delivers actionable insights for care teams and longer-term analytics for stakeholders such as surgeons, and offers virtual, real-time access to outside experts. Caresyntax's software is used in more than 4,000 operating rooms worldwide and supports surgical teams in over two million procedures per year. The company plans to use new funds to continue developing its platform and to advance new data solutions that support value-based care providers. The product emphasis is on improving patient outcomes through immediate and longer-term insights derived from real-world OR data. The company was founded by Dennis Kogan and Björn von Siemens. Caresyntax provides an enterprise-grade digital surgery platform that uses proprietary software and AI to analyze large volumes of video, audio, images, device, clinical, and operational data in and around the operating room. Its platform delivers real-world evidence that care teams can use live during procedures via a telehealth link and post-procedure for benchmarking and improvement. Hospitals can use the platform to manage surgical resources more efficiently, medical device companies can advance products, and insurers can better understand risk. The software is used in more than 4,000 operating rooms worldwide and supports surgical teams in over two million procedures per year. The company announced the acquisition of Syus at the close of 2019, extending its hospital footprint and analytics capabilities. Caresyntax intends to use the new funding to accelerate expansion in key markets, further R&D of its AI analytics, build out its platforms, and grow its employee base. caresyntax provides surgical intelligence and automation solutions that leverage IoT, analytics and AI to integrate data from medical devices, EHRs and other OR sources into a unified platform. Its offerings automate clinical and operational decision support for surgical teams and support outcome contributors across risk-bearing contracts. The company says its technologies are used in more than 7,000 operating rooms worldwide and support over 10 million procedures per year. Recent partnerships with organizations including Mitsubishi’s MC Healthcare, Barco Healthcare, Insel Gruppe AG and University of Wisconsin–Madison aim to expand R&D and global reach. caresyntax plans to use new capital to accelerate domestic and international growth and to further develop and deploy its surgical intelligence and automation technologies. The company works with providers, insurers and device vendors to inform device improvements, support data-driven underwriting and enable value-based contracting. Caresyntax provides a vendor-neutral platform that aggregates structured and unstructured data from operating room devices, electronic health records and other sources into unified dashboards for surgeons and hospital decision makers. Its offerings include PRIME365 OR integration and qvident surgical performance management software, which aim to reduce documentation time, automate workflows, and generate quality data for training and decision support. The company emphasizes granular analysis of surgical variation to recommend fixes that reduce readmissions, improve patient safety and streamline clinical workflows. Caresyntax reports an installed base of more than 6,000 operating rooms, supports over 10 million procedures per year and generates roughly 100 petabytes of high-fidelity data annually. It was launched in 2013 in Germany and established full-time North American operations and a headquarters in Boston in October. The company says it will use the new financing to grow its U.S. business and to develop machine learning and value-added applications for surgical risk management.

Led · Equity · Jan 2018

NUUBO develops textile medical electronics and wireless sensors for cardiac monitoring, including a system that records ECG to detect and diagnose irregular heart rhythms and help prevent cardiovascular events. The company was founded in 2005 and has offices in Paterna and Madrid. NUUBO’s monitoring system is positioned toward clinical detection of arrhythmias and cardiovascular risk prevention. The company closed a €270,000 financing intended to support its expansion into the United States. The financing was led by a health-focused coinvestment vehicle, reflecting investor interest from public and private backers. No operating metrics were disclosed in the article. Nuubo designs, manufactures and sells a proprietary wearable wireless ECG system comprised of a comfortable textile Holter (no adhesives, no wires) and arrhythmia analysis software. The CE-marked system offers up to 60 days of cardiac monitoring and has demonstrated over 20% diagnostic yield for atrial fibrillation in cryptogenic stroke during a 30-day monitoring period. The product fills a gap between short-term non-invasive monitors (7–14 days) and long-term invasive implants, targeting improved detection of arrhythmias such as atrial fibrillation. Nuubo holds several patents in the EU and USA and is certified to ISO 27001, ISO 13485 and ISO 9001. The company is headquartered in Madrid with R&D and manufacturing facilities in Valencia, Spain, and is supported by Spanish VCs including Cross Roads Biotech Inverbio, Caixa and Fides Capital. The announced financing is intended to accelerate growth, expand commercial presence in Europe and the US, and fund clinical trials and new product development. Nuubo develops biomedical garments and a platform that simplify heart monitoring by enabling continuous, cable-free electrocardiogram (ECG) readings in dynamic environments. Its platform, the nECG DYNAMIC PLATFORM, allows users to perform and read ECGs remotely. The company says its solution removes the need for cables, requiring only a piece of clothing to monitor cardiac activity. Nuubo started commercial activities in 2012 and has a production centre in Paterna (Valencia) and 22 employees in Madrid. It intends to use the new funds to position itself in the main European markets. The company expects to exceed €1m in sales in 2014.

Led · Equity · Nov 2017

pritidenta GmbH develops and sells high‑aesthetic ceramic materials for prosthetic dental products, focused on the CAD/CAM and 3D printing segments. Its main offering is zirconia (ZrO2) blank discs for crowns, bridges, full‑contour restorations, veneers, inlays and onlays. The flagship priti®multidisc is produced from high‑purity zirconium dioxide in three translucency grades and is available as monochromatic discs in 16 shades or multicolour discs in seven gradients. The company is described as a young German high‑tech firm and innovation leader in digital dental prosthetic materials. pritidenta is developing next‑generation ceramics and chair‑side and 3D‑printing ceramic materials and intends to accelerate product development and global commercial expansion. The business is supported by TVM Capital Life Science and has received new financing to fund its growth.